Exact SciencesEXAS
Market Cap: $10.9B
About: Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Employees: 6,600
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
22% more repeat investments, than reductions
Existing positions increased: 208 | Existing positions reduced: 171
20% more call options, than puts
Call options by funds: $91.9M | Put options by funds: $76.5M
6.88% more ownership
Funds ownership: 89.99% [Q1] → 96.87% (+6.88%) [Q2]
13% less funds holding
Funds holding: 604 [Q1] → 527 (-77) [Q2]
33% less capital invested
Capital invested by funds: $11.3B [Q1] → $7.55B (-$3.71B) [Q2]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 4 (-3) [Q2]
55% less first-time investments, than exits
New positions opened: 64 | Existing positions closed: 141
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Wells Fargo Brandon Couillard 36% 1-year accuracy 4 / 11 met price target | 27%upside $75 | Overweight Initiated | 27 Aug 2024 |
Benchmark Bruce Jackson 27% 1-year accuracy 13 / 48 met price target | 13%upside $67 | Buy Maintained | 1 Aug 2024 |
Stifel Daniel Arias 58% 1-year accuracy 11 / 19 met price target | 39%upside $82 | Buy Maintained | 1 Aug 2024 |
Goldman Sachs Matthew Sykes 70% 1-year accuracy 37 / 53 met price target | 27%upside $75 | Buy Maintained | 17 Jul 2024 |
Evercore ISI Group Vijay Kumar 90% 1-year accuracy 27 / 30 met price target | 22%upside $72 | Outperform Maintained | 2 Jul 2024 |
Financial journalist opinion
Based on 10 articles about EXAS published over the past 30 days